Clinical trials: Diffuse Parenchymal Lung Diseases
Fibrosis, Lung Disease
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress…
- Conditions
- Fibrosis, Lung Disease, Respiratory Disorders, Respiratory Distress Syndrome, Adult
- Trial name
- NCT00455767
- Testing
- EPI-hNE4
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- Debiopharm International SA
Interstitial Lung Diseases (ILD), Airway Disease
Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)
This study focuses on both hospitalized and outpatient populations. Through a multicenter, retrospective study, it aims to comprehensively characterize:The comorbidity of interstitial lung diseases (ILD) and airway diseases;The…
- Trial name
- EDCS-LIAD (NCT06987266)
- Testing
- no intervention
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Xiangya Hospital of Central South University
Interstitial Lung Disease
Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea
Patients with interstitial lung disease (ILD) experience distressing activity-related respiratory discomfort which is challenging to manage therapeutically.
- Trial name
- NCT03018756
- Testing
- Fentanyl Citrate
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Dr. Denis O'Donnell
Idiopathic Pulmonary Fibrosis
Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level.
- Trial name
- NCT03727802
- Testing
- TRK-250
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Toray Industries, Inc
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Langerhans Cell Histiocytosis
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric…
- Trial name
- NCT06582745
- Testing
- Trametinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cook Children's Health Care System
Pulmonary Fibrosis
Explanted Lung Tissues With Pulmonary Fibrosis
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
- Trial name
- NCT00515567
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
ILD
Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using non-invasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
- Trial name
- Xe MRI in ILD (NCT06012500)
- Testing
- Xenon-129
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cardiac Failure
The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with heart failure and preserved left ventricular…
- Trial name
- PIROUETTE (NCT02932566)
- Testing
- Pirfenidone
- Where
- United Kingdom
- Volunteers
- 129 people
- Sponsor
- Manchester University NHS Foundation Trust
Interstitial Lung Diseases
Confocal Laser Endomicroscopy and Optical Coherence Tomography for Diagnosing ILD.
Often, assessing a classifying diagnosis in patients with interstitial lung disease provides a diagnostic challenge. Currently HRCT, endoscopic or surgical video assisted thoracoscopic surgery(VATS) assessment including lung…
- Trial name
- NCT02689102
- Testing
- Probe based optical techniques
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Bone Marrow Failure Syndrome, Severe Aplastic Anemia
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the…
- Conditions
- Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia
- Trial name
- NCT01966367
- Testing
- CD34 Stem Cell Selection Therapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Diane George
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Lung Diseases, Interstitial
Interstitial Lung Disease (ILD). Diagnostic Yield of Surgical Lung Biopsy Versus Cryobiopsy in the Same Surgical Stage.
In patients with interstitial lung disease (ILD) with inconsistent clinical and radiological features, establishing a reliable diagnosis of ILD requires a surgical lung biopsy Transbronchial cryobiopsy is a minimally invasive…
- Trial name
- NCT03596528
- Testing
- Lung biopsy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Clinic of Barcelona
Wegeners Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive…
- Trial name
- SPARROW (NCT01446211)
- Testing
- Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- Nordic Pharma SAS
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Interstitial Lung Disease, Sarcoidosis
Interstitial Lung Disease Research Unit Biobank
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Trial name
- ILDRU (NCT05392881)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center
Systemic Sclerosis, Interstitial Lung Disease
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of…
- Trial name
- LUNGSCLEROCT (NCT05482607)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Vasculitis, Microscopic Polyangiitis
Alemtuzumab for ANCA Associated Refractory Vasculitis
Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among…
- Conditions
- Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis, Wegener's
- Trial name
- ALEVIATE (NCT01405807)
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pulmonary Fibrosis, Anxiety
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.
- Trial name
- COMPANION (NCT05330312)
- Testing
- Digital cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Vicore Pharma AB
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Rituximab Vasculitis Maintenance Study
Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect wears off and the disease can return.
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- RITAZAREM (NCT01697267)
- Testing
- Rituximab, Azathioprine
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.